665 results on '"Siccardi, Marco"'
Search Results
202. Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks
203. PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING
204. Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir
205. Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens
206. A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance
207. Intracellular Accumulation of Tipranavir/Ritonavir
208. Is Maraviroc a substrate for SLCO1B1?
209. ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina
210. PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations
211. Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor
212. A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients
213. Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens
214. Unexpected drug-drug interaction between tipranavir/ritonavir (TPV/RTV) and enfuvirtide (T20)
215. A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo.
216. 'Variazione dell'Onda Flussimetrica dell'Arteria Uterina in seguito alla Manovra di Inibizione su L5-S1'
217. Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine
218. CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults
219. Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro
220. Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
221. Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor
222. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment
223. Prophylactic Drug Monitoring of Itraconazole in an Oncohematological Pediatric Patient Population
224. Efavirenz in an Obese HIV-Infected Patient – a Report and An In Vitro–In Vivo Extrapolation Model Indicate Risk of Underdosing
225. Video. Incontri di acquaticità in gravidanza e con il bambino nei primi mesi (prepararsi con l'acqua al travaglio di parto e al ruolo di madre)
226. Proposta di organizzazione di un servizio di analgesia ostetrica
227. Frequenza ai corsi di preparazione al parto e andamento del travaglio di parto
228. Divalent Metals and pH Alter Raltegravir Disposition In Vitro
229. Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
230. Inosine Triphosphatase Polymorphisms and Ribavirin Pharmacokinetics as Determinants of Ribavirin-Associate Anemia in Patients Receiving Standard Anti-HCV Treatment
231. Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study
232. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS
233. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4
234. Evaluation of the Mean Corpuscular Volume of Peripheral Blood Mononuclear Cells of HIV Patients by a Coulter Counter To Determine Intracellular Drug Concentrations
235. Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir
236. Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients
237. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism
238. Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
239. Development, Validation, and Routine Application of a High-Performance Liquid Chromatography Method Coupled with a Single Mass Detector for Quantification of Itraconazole, Voriconazole, and Posaconazole in Human Plasma
240. Raltegravir Penetration in Seminal Plasma of Healthy Volunteers
241. A Validated High-Performance Liquid Chromatography-Ultraviolet Method for Quantification of the CCR5 Inhibitor Maraviroc in Plasma of HIV-Infected Patients
242. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma
243. New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
244. Simultaneous Quantification of Linezolid, Rifampicin, Levofloxacin, and Moxifloxacin in Human Plasma Using High-Performance Liquid Chromatography With UV
245. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method
246. An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients
247. Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir
248. Data analysis and phase ambiguity removal in the ACES microwave link
249. Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens
250. Corrigendum to “HPLC–MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients” [J. Chromatogr. B 859 (2007) 234–240]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.